Company developing patient-specific immunotherapies for cancer.
At BioNTech we understand that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized.
To pioneer the next generation of patient-specific immunotherapies, we have combined ground-breaking research with cutting-edge technologies to develop therapeutics for cancer and beyond. Our broad and synergistic suite of platforms, which include mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators have been optimized for distinct modes of action, high precision targeting, high potency and efficacy. We are also developing in parallel our own state-of-the-art manufacturing processes to complement our drug development platforms.
Visit website: https://biontech.de/
People at BioNTech
Co-Founder and Chief Medical Officer of BioNTech
Professor Medicine at University of Mainz and Co-Founder and CEO of BioNTech.
BioNTech begins human trials for mRNA therapy targeting colon cancer and melanoma
Lifespan.io (LEAF) - 10-Sep-2021
mRNA cocktail treatment shows anti-tumor effect without toxic side effects in miceRead more...
Cancer vaccines based on mRNA technology will be available soon
Sky News - 19-Mar-2021
Science behind developing Covid-19 vaccines could bring us cancer shots tooRead more...
BioNTech's vaccine prevents multiple sclerosis in rodents
FierceBiotech - 07-Jan-2021
Developed through a novel mRNA technology used in vaccine for COVID-19Read more...
Personalized cancer vaccines vanquish melanoma
Scientific American - 06-Jul-2017
Six melanoma patients given an experimental, custom-made, neoantigen vaccine. None of their tumo...Read more...
Could mRNA Overtake all other Biologicals in Medicine?
Labiotech - 05-Jan-2016
What if we could send the body an instruction to produce its own drug? RNA strand seems easier t...Read more...